 Proactive Investors USA & Canada | Biotech Investing Lessons Learned: Diversify, Be Patient Seeking Alpha In Biogen's case, results are for daclizumab for multiple sclerosis and for BG-12 for MS as well. Onyx's results are for regorafenib for metastatic colorectal cancer, which is being developed by Bayer, but for which Onyx gets royalties. ... Biogen Idec (BIIB) Shares Given New $127.00 Price Target by Oppenheimer (OPY ... Analysts rave over Biogen MS pill on second Phase III success Stocks to watch Monday: Mattel, Biogen Idec |
